Kings Path Partners’s Editas Medicine EDIT Stock Holding History

Kings Path Partners’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,000	Closed	-$1.27K	–	269
2024 Q4	$1.27K	Buy	+1,000	New	+$2.55K	﹤0.01%	274

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Kings Path Partners's EDIT Position: Q1 2025 in Review

Kings Path Partners sold out of Editas Medicine (EDIT) in Q1 2025, closing a stake of 1,000 shares — an estimated $1.27K sold.

Kings Path Partners first reported a position in EDIT in Q4 2024 and held it in 1 quarter. The position peaked at $1.27K in Q4 2024. 194 funds tracked by Wall St. Rank hold EDIT as of Q1 2025.

Kings Path Partners reported no remaining Editas Medicine position as of Q1 2025 after selling out during the quarter.
Kings Path Partners sold 1,000 Editas Medicine shares in Q1 2025, an estimated $1.27K.
Kings Path Partners first reported a position in Editas Medicine in Q4 2024 and held it in 1 quarter.
Kings Path Partners's Editas Medicine position peaked at $1.27K in Q4 2024.
194 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2025.

Based on Kings Path Partners's 13F filing for Q1 2025, filed 4 Apr 2025.